{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:51:30Z","timestamp":1793314290280,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-24916-1","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:49:59Z","timestamp":1763016599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness analysis of different types of human papillomavirus vaccination to prevent cervical cancer in Iran"],"prefix":"10.1186","volume":"25","author":[{"given":"Negin","family":"Bashari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Davari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Akbarisari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Khorasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajabali","family":"Daroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"24916_CR1","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2018. 2018."},{"key":"24916_CR2","doi-asserted-by":"publisher","first-page":"552028","DOI":"10.3389\/fpubh.2020.552028","volume":"8","author":"AJ Kombe Kombe","year":"2020","unstructured":"Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, et al. Epidemiology and burden of human papillomavirus and related Diseases, molecular Pathogenesis, and vaccine evaluation. Front Public Health. 2020;8:552028.","journal-title":"Front Public Health"},{"key":"24916_CR3","volume-title":"Cervical cancer, human papillomavirus (HPV), and HPV vaccines: key points for policy-makers and health professionals","author":"WH Organization","year":"2007","unstructured":"Organization WH. Cervical cancer, human papillomavirus (HPV), and HPV vaccines: key points for policy-makers and health professionals. Geneva, Switzerland: World Health Organization; 2007."},{"issue":"3","key":"24916_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000502824","volume":"62","author":"Z Shoja","year":"2019","unstructured":"Shoja Z, Farahmand M, Hosseini N, Jalilvand S. A meta-analysis on human papillomavirus type distribution among women with cervical neoplasia in the WHO eastern mediterranean region. Intervirology. 2019;62(3):101\u201311.","journal-title":"Intervirology"},{"issue":"2","key":"24916_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ygyno.2012.11.032","volume":"128","author":"F Khorasanizadeh","year":"2013","unstructured":"Khorasanizadeh F, Hassanloo J, Khaksar N, Taheri SM, Marzaban M, Rashidi BH, et al. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women\u2014analyses of national data and systematic review of the literature. Gynecol Oncol. 2013;128(2):277\u201381.","journal-title":"Gynecol Oncol"},{"key":"24916_CR6","volume-title":"Human Papillomavirus and Related Diseases in Iran (Islamic Republic of)","author":"L Bruni","year":"2023","unstructured":"Bruni L, Albero G, Serrano B, Mena M, Collado JJ, G\u00f3mez D, et al. Human Papillomavirus and Related Diseases in Iran (Islamic Republic of). IARC Information Centre on HPV and Cancer (HPV Information Centre); 2023."},{"issue":"161","key":"24916_CR7","first-page":"108","volume":"28","author":"Z Vafaeinezhad","year":"2018","unstructured":"Vafaeinezhad Z, Kazemi Z, Mirmoeini M, Piroti H, Sadeghian E, Mohammad Ali-Vajari M, et al. Trends in cervical cancer incidence in Iran according to National cancer registry. J Mazandaran Univ Med Sci. 2018;28(161):108\u201314.","journal-title":"J Mazandaran Univ Med Sci"},{"issue":"8","key":"24916_CR8","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1002\/jmv.26928","volume":"93","author":"Z Salavatiha","year":"2021","unstructured":"Salavatiha Z, Farahmand M, Shoja Z, Jalilvand S. A meta-analysis of human papillomavirus prevalence and types among Iranian women with normal cervical cytology, premalignant lesions, and cervical cancer. J Med Virol. 2021;93(8):4647\u201358.","journal-title":"J Med Virol"},{"issue":"3","key":"24916_CR9","doi-asserted-by":"publisher","first-page":"e00553","DOI":"10.34172\/jrhs.2022.88","volume":"22","author":"Z Shalchimanesh","year":"2022","unstructured":"Shalchimanesh Z, Ghane M, Kalantar E. Prevalence of human papillomavirus genotypes in Tehran, Iran. J Res Health Sci. 2022;22(3):e00553.","journal-title":"J Res Health Sci"},{"issue":"1","key":"24916_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/03630242.2020.1822490","volume":"61","author":"Z Farahmand","year":"2021","unstructured":"Farahmand Z, Soleimanjahi H, Garshasbi M, Hasanzadeh M, Zafari E. Distribution of the most common types of HPV in Iranian women with and without cervical cancer. Women Health. 2021;61(1):73\u201382.","journal-title":"Women Health"},{"issue":"11","key":"24916_CR11","first-page":"2313","volume":"52","author":"N Pirani","year":"2023","unstructured":"Pirani N, Jafari M, Bagherzadeh R, Keikhosravi M, Pirani H. Cervical cancer prevention, its challenges and solutions in Iran and worldwide: a systematic review. Iran J Public Health. 2023;52(11):2313\u201324.","journal-title":"Iran J Public Health"},{"issue":"11","key":"24916_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048\u201356.","journal-title":"Lancet Oncol"},{"issue":"6","key":"24916_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1086\/597071","volume":"199","author":"SM Garland","year":"2009","unstructured":"Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805\u201314.","journal-title":"J Infect Dis"},{"issue":"10","key":"24916_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","volume":"12","author":"T Malag\u00f3n","year":"2012","unstructured":"Malag\u00f3n T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"24916_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","volume":"103","author":"AB Mariotto","year":"2011","unstructured":"Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010\u20132020. J Natl Cancer Inst. 2011;103(2):117\u201328.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"24916_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3111\/13696998.2010.490481","volume":"13","author":"N Demarteau","year":"2010","unstructured":"Demarteau N, Standaert B. Modelling the economic value of cross-and sustained-protection in vaccines against cervical cancer. J Med Econ. 2010;13(2):324\u201338.","journal-title":"J Med Econ"},{"issue":"11","key":"24916_CR17","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1111\/ajt.15633","volume":"19","author":"E Meites","year":"2019","unstructured":"Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. Am J Transplant. 2019;19(11):3202\u20136.","journal-title":"Am J Transplant"},{"key":"24916_CR18","unstructured":"World Health Organization. Global Health Observatory (GHO) data.Life tables Iran. Available from: http:\/\/apps.who.int\/gho\/data\/?theme=main&vid=60760. Cited 2018 April 20."},{"key":"24916_CR19","volume-title":"National guide to the care and treatment of sexual infections","author":"MT Gouya","year":"2015","unstructured":"Gouya MT, Afsarkazerouni K, Farhoudi P, Souri B, Emadi TH. National guide to the care and treatment of sexual infections. Tehran, Iran: Andishmand; 2015."},{"key":"24916_CR20","doi-asserted-by":"crossref","unstructured":"Sargazi N, Takian A, Daroudi R, Nahvijou A, Yaseri M, Ghanbari Motlagh A et al. Cost\u2013Benefit analysis of human papillomavirus vaccine in Iran. J Prev. 2022:1\u201317.","DOI":"10.21203\/rs.3.rs-745058\/v1"},{"issue":"6","key":"24916_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/sextrans-2011-050073","volume":"87","author":"S Woodhall","year":"2011","unstructured":"Woodhall S, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011;87(6):458\u201363.","journal-title":"Sex Transm Infect"},{"issue":"1","key":"24916_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1471-2458-11-203","volume":"11","author":"VJ Lee","year":"2011","unstructured":"Lee VJ, Tay SK, Teoh YL, Tok MY. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health. 2011;11(1):203.","journal-title":"BMC Public Health"},{"key":"24916_CR23","doi-asserted-by":"publisher","unstructured":"Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Reviews. 2018;9;5(5).\u00a0https:\/\/doi.org\/10.1002\/14651858.CD009069.","DOI":"10.1002\/14651858.CD009069"},{"issue":"10","key":"24916_CR24","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1017\/S0950268817000747","volume":"145","author":"C Signorelli","year":"2017","unstructured":"Signorelli C, Odone A, Ciorba V, Cella P, Audisio R, Lombardi A, et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect. 2017;145(10):1962\u201382.","journal-title":"Epidemiol Infect"},{"issue":"8","key":"24916_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"24916_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156705","volume":"11","author":"A Nahvijou","year":"2016","unstructured":"Nahvijou A, Daroudi R, Tahmasebi M, Amouzegar Hashemi F, Rezaei Hemami M, Akbari Sari A, et al. Cost-effectiveness of different cervical screening strategies in Islamic Republic of Iran: a middle-income country with a low incidence rate of cervical cancer. PLoS ONE. 2016;11(6):e0156705.","journal-title":"PLoS ONE"},{"key":"24916_CR27","unstructured":"Merck. & CO. I. Highlights of prescribing information: GARDASIL\u00ae9 (Human papillomavirus 9- valent vaccine, recombinant). https:\/\/www.merck.com\/product\/patent\/home.html."},{"key":"24916_CR28","unstructured":"WorldHealthOrganization. Life tables for Iran (Islamic Republic of). Global Health Observatory data repository2018."},{"issue":"19","key":"24916_CR29","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.vaccine.2018.03.024","volume":"36","author":"SS Ng","year":"2018","unstructured":"Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine. 2018;36(19):2529\u201344.","journal-title":"Vaccine"},{"issue":"6","key":"24916_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"Cancer J Clin"},{"issue":"7","key":"24916_CR31","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1086\/597307","volume":"199","author":"DR Brown","year":"2009","unstructured":"Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years. J Infect Dis. 2009;199(7):926\u201335.","journal-title":"J Infect Dis"},{"key":"24916_CR32","first-page":"1289","volume":"11","author":"MK Zarchi","year":"2010","unstructured":"Zarchi MK, Akhavan A, Fallahzadeh H, Gholami H, Dehghani A, Teimoori S. Outcome of cervical cancer in Iranian patients according to tumor histology, stage of disease and therapy. Asian Pac J Cancer Prev. 2010;11:1289\u201391.","journal-title":"Asian Pac J Cancer Prev"},{"key":"24916_CR33","unstructured":"Afrakhteh M, Khodakarami N, Moradi A, Alavi E, Shirazi FH. A study of 13315 Papanicolau smear diagnoses in Shohada hospital. J Family Reproductive Health. 2007:74\u20138."},{"issue":"1","key":"24916_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","volume":"13","author":"CM Wheeler","year":"2012","unstructured":"Wheeler CM, Castellsagu\u00e9 X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100\u201310.","journal-title":"Lancet Oncol"},{"issue":"2","key":"24916_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/jmv.24053","volume":"87","author":"S Jalilvand","year":"2015","unstructured":"Jalilvand S, Shoja Z, Nourijelyani K, Tohidi HR, Hamkar R. Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: implications for screening and vaccination. J Med Virol. 2015;87(2):287\u201395.","journal-title":"J Med Virol"},{"issue":"7","key":"24916_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","volume":"21","author":"AA Leech","year":"2018","unstructured":"Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and misuse of cost-effectiveness analysis thresholds in low-and middle-income countries: trends in cost-per-DALY studies. Value Health. 2018;21(7):759\u201361.","journal-title":"Value Health"},{"issue":"1","key":"24916_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/21645515.2015.1065363","volume":"12","author":"B Romanowski","year":"2016","unstructured":"Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, et al. Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother. 2016;12(1):20\u20139.","journal-title":"Hum Vaccin Immunother"},{"key":"24916_CR38","unstructured":"Iran Pharmacoeconomics Committee. Executive Manual for Submitting a Pharmaceutical Economic Evaluation Study; Working Group for Reviewing and Compiling the Iranian Drug List. Tehran, Iran: Iran Food and Drug Administrtion 2021. p. 7."},{"key":"24916_CR39","unstructured":"Organization WH. Macroeconomics and health: investing in health for economic development: report of the Commission on Macroeconomics and Health. Geneva, 2001. p. 202-.\u00a0https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/wha55\/ea555.pdf."},{"key":"24916_CR40","unstructured":"The World Bank. Countries and Economies. The World Bank. 2019; Available from: http:\/\/data.worldbank.org\/country"},{"issue":"1","key":"24916_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/21645515.2015.1058458","volume":"12","author":"M Hern\u00e1ndez-\u00c1vila","year":"2016","unstructured":"Hern\u00e1ndez-\u00c1vila M, Torres-Ibarra L, Stanley M, Salmer\u00f3n J, Cruz-Valdez A, Munoz N, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother. 2016;12(1):30\u20138.","journal-title":"Hum Vaccin Immunother"},{"key":"24916_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12962-020-00256-2","volume":"19","author":"R Hashempour","year":"2021","unstructured":"Hashempour R, Raei B, Safaei Lari M, Abolhasanbeigi Gallezan N, AkbariSari A. QALY league table of Iran: a practical method for better resource allocation. Cost Eff Resour Alloc. 2021;19:1\u201311.","journal-title":"Cost Eff Resour Alloc"},{"key":"24916_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12962-021-00260-0","volume":"19","author":"R Daroudi","year":"2021","unstructured":"Daroudi R, Akbari Sari A, Nahvijou A, Faramarzi A. Cost per DALY averted in low, middle-and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds. Cost Eff Resour Alloc. 2021;19:1\u20139.","journal-title":"Cost Eff Resour Alloc"},{"key":"24916_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12962-019-0172-9","volume":"17","author":"N Moradi","year":"2019","unstructured":"Moradi N, Rashidian A, Nosratnejad S, Olyaeemanesh A, Zanganeh M, Zarei L. Willingness to pay for one quality-adjusted life year in Iran. Cost Eff Resour Alloc. 2019;17:1\u201310.","journal-title":"Cost Eff Resour Alloc"},{"key":"24916_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.vhri.2018.03.001","volume":"15","author":"M Yaghoubi","year":"2018","unstructured":"Yaghoubi M, Nojomi M, Vaezi A, Erfani V, Mahmoudi S, Ezoji K, et al. Cost-effectiveness analysis of the introduction of HPV vaccination of 9-year-old-girls in Iran. Value Health Reg Issues. 2018;15:112\u20139.","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"24916_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14760584.2018.1411195","volume":"17","author":"OA Silas","year":"2018","unstructured":"Silas OA, Achenbach CJ, Murphy RL, Hou L, Sagay SA, Banwat E, et al. Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature. Expert Rev Vaccines. 2018;17(1):91\u20138.","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"24916_CR47","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","volume":"2","author":"M Jit","year":"2014","unstructured":"Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2(7):e406-14.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"24916_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-017-4064-7","volume":"17","author":"AE Bardach","year":"2017","unstructured":"Bardach AE, Garay OU, Calder\u00f3n M, Pich\u00f3n-Rivi\u00e9re A, Augustovski F, Mart\u00ed SG, et al. Health economic evaluation of human papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health. 2017;17(1):1\u201315.","journal-title":"BMC Public Health"},{"issue":"26","key":"24916_CR49","first-page":"2568","volume":"372","author":"E Joura","year":"2015","unstructured":"Joura E, Bautista O, Luxembourg A. A 9-valent HPV vaccine in women. N Engl J Med. 2015;372(26):2568\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"24916_CR50","doi-asserted-by":"publisher","first-page":"693","DOI":"10.21149\/9810","volume":"60","author":"C Robles","year":"2018","unstructured":"Robles C, Hernandez ML, Almonte M. Alternative HPV vaccination schedules in Latin America. Salud Publica Mex. 2018;60(6):693\u2013702.","journal-title":"Salud Publica Mex"},{"issue":"1","key":"24916_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13012-018-0846-2","volume":"13","author":"C Soi","year":"2018","unstructured":"Soi C, Gimbel S, Chilundo B, Muchanga V, Matsinhe L, Sherr K. Human papillomavirus vaccine delivery in Mozambique: identification of implementation performance drivers using the consolidated framework for implementation research (CFIR). Implement Sci. 2018;13(1):151.","journal-title":"Implement Sci"},{"key":"24916_CR52","unstructured":"Organization WH. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva, 2020.\u00a0https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/4e245e89-ddcc-488f-97c7-9de5e08524ef\/content."},{"issue":"10224","key":"24916_CR53","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","volume":"395","author":"K Canfell","year":"2020","unstructured":"Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):591\u2013603.","journal-title":"Lancet"},{"issue":"19","key":"24916_CR54","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928\u201343.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"24916_CR55","first-page":"225","volume":"13","author":"M Khatibi","year":"2014","unstructured":"Khatibi M, Rasekh HR, Shahverdi Z. Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran. Iran J Pharm Research: IJPR. 2014;13(Suppl):225.","journal-title":"Iran J Pharm Research: IJPR"},{"issue":"5","key":"24916_CR56","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jval.2012.02.012","volume":"15","author":"N Demarteau","year":"2012","unstructured":"Demarteau N, Tang C-H, Chen H-C, Chen C-J, Van Kriekinge G. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Value Health. 2012;15(5):622\u201331.","journal-title":"Value Health"},{"issue":"1","key":"24916_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-017-2592-5","volume":"17","author":"X Mo","year":"2017","unstructured":"Mo X, Tobe RG, Wang L, Liu X, Wu B, Luo H, et al. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in Mainland China. BMC Infect Dis. 2017;17(1):1\u201312.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"24916_CR58","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1080\/21645515.2016.1269991","volume":"13","author":"MJ Germar","year":"2017","unstructured":"Germar MJ, Purugganan C, Bernardino MS, Cuenca B, Chen Y-C, Li X, et al. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16\/18 vaccine compared with human papillomavirus 6\/11\/16\/18 vaccine in the Philippines, with the new 2-dose schedule. Hum Vaccin Immunother. 2017;13(5):1158\u201366.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"24916_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-11-203","volume":"11","author":"VJ Lee","year":"2011","unstructured":"Lee VJ, Tay SK, Teoh YL, Tok MY. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health. 2011;11(1):1\u201311.","journal-title":"BMC Public Health"},{"issue":"1","key":"24916_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-12-872","volume":"12","author":"M Kohli","year":"2012","unstructured":"Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6\/11\/16\/18 vaccine in Canada. BMC Public Health. 2012;12(1):1\u201317.","journal-title":"BMC Public Health"},{"issue":"6","key":"24916_CR61","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24916-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-24916-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24916-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:03:21Z","timestamp":1763021001000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-24916-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24916"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-24916-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval from the Tehran University of Medical Sciences with code IR.TUMS.VCR.REC.1398.481. Since we had no contact with the patients, consent to participate in the study was not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Our manuscript does not contain individual data in any form, and therefore consent for publication does not apply to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"3927"}}